Vor Bio, Inc. has entered into an exclusive global licensing agreement with Chinese biopharmaceutical company RemeGen Co., Ltd., gaining rights to develop and commercialize the autoimmune drug telitacicept outside of China, Hong Kong, Macau, and Taiwan. The deal marks a strategic pivot for Vor Bio toward autoimmune disease and includes an upfront value of $125 million, with potential milestone payments exceeding $4 billion.
Under the agreement, Vor Bio will pay $45 million in cash and issue $80 million in stock warrants to RemeGen. The company will also pay tiered royalties and is eligible for regulatory and commercial milestone payments if telitacicept achieves key development goals.
Telitacicept is a dual-target fusion protein that blocks BAFF and APRIL—two cytokines involved in B-cell survival and autoantibody production. It is already approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). A global Phase 3 trial is underway and enrolling patients in the U.S., Europe, and South America, with top-line data expected in the first half of 2027.
“This is a transformative milestone for RemeGen and the global reach of telitacicept,” said Dr. Jianmin Fang, CEO of RemeGen. “Vor Bio’s capabilities make them an ideal partner to bring this therapy to patients worldwide.”
In parallel with the licensing announcement, Vor Bio also named Dr. Jean-Paul Kress as its new CEO and Chairman of the Board, effective immediately. Dr. Robert Ang has stepped down but will remain as a strategic advisor through October 2025.
Dr. Kress, formerly CEO of MorphoSys and Syntimmune, brings a strong track record in immunology and oncology leadership. “I am absolutely thrilled to be leading Vor Bio as we transform into a major player in autoimmune disease treatment,” he said. “Telitacicept is a differentiated, clinically advanced asset that we believe can make a real impact for patients with serious autoimmune conditions.”
The dual developments mark a new chapter for Vor Bio as it expands beyond its origins in cell therapy into broader autoimmune drug development.